Caitlin John’s Iovance Biotherapeutics IOVA Stock Holding History

Caitlin John’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$291	Hold	70	–	–	﹤0.01%	964
2026 Q1	$246	Hold	70	–	–	﹤0.01%	891
2025 Q4	$191	Hold	70	–	–	﹤0.01%	896
2025 Q3	$152	Buy	+70	New	+$165	﹤0.01%	850

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Caitlin John's IOVA Position: Q2 2026 in Review

Caitlin John held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 70 shares worth $291. The position accounts for ﹤0.01% of the portfolio, ranked #964.

Caitlin John first reported a position in IOVA in Q3 2025 and has held it in 4 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Caitlin John held 70 shares of Iovance Biotherapeutics worth $291 as of Q2 2026.
Caitlin John left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of Caitlin John's portfolio in Q2 2026, its #964 holding.
Caitlin John first reported a position in Iovance Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Caitlin John's 13F filing for Q2 2026, filed 17 Aug 2026.